Ciprofloxacin (Bay-09867)

Alias: Bay-09867; Baflox; Cetraxal; Ciprolin; Bay09867; Fimoflox; Bay 09867;Proflaxin; Spitacin

Cat No.:V1402 Purity: ≥98%

COA Product Data Instructions for use SDS

Ciprofloxacin (formerly known as Bay-09867;Bay09867;Baflox; Cetraxal; Ciprolin; Fimoflox; Proflaxin; Spitacin) is a broad-spectrum, fluoroquinolone class of antibiotic/antimicrobial which shows an MIC90 (minimal inhibitory concentrations for 90%) of between 0.008 and 2 μg/ml against various bacteria including Enterobacteriaceae, Haemophilus influenzae, Pseudomonas aeruginosa,Neisseria gonorrhoeae, Staphylococcus aureus,streptococci, and Bacteroidesfragilis strains.

Ciprofloxacin (Bay-09867) Chemical Structure CAS No.: 85721-33-1
Product category: Topoisomerase

This product is for research use only, not for human use. We do not sell to patients.

Size	Price	Stock	Qty
2g
5g
10g
25g
Other Sizes

ADD TO CART CHECKOUT BULK INQUIRY

1-708-310-1919 sales@invivochem.com

Other Forms of Ciprofloxacin (Bay-09867):

Official Supplier of:

Top Publications Citing lnvivochem Products

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

Purity & Quality Control Documentation

Current batch：

Purity: ≥98%

COA

MSDS

Instructions

Product Description
Bioactivity & Protocols
Physicochemical Properties
Solubility Data
Calculators
Clinical Trial Information
Biological Data

Product Description

Ciprofloxacin (formerly known as Bay-09867; Bay09867; Baflox; Cetraxal; Ciprolin; Fimoflox; Proflaxin; Spitacin) is a broad-spectrum, fluoroquinolone class of antibiotic/antimicrobial which shows an MIC90 (minimal inhibitory concentrations for 90%) of between 0.008 and 2 μg/ml against various bacteria including Enterobacteriaceae, Haemophilus influenzae, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Staphylococcus aureus, streptococci, and Bacteroidesfragilis strains. Ciprofloxacin inhibits gyrase as a secondary target and topoisomerase IV as a primary target of topoisomerase.

Biological Activity I Assay Protocols (From Reference)

Targets

Topoisomerase IV

ln Vitro

Ciprofloxacin (Bay-09867) (5-50 μg/mL; 0-24 h; tendon cells) induces cell cycle arrest at the G2/M phase and suppresses cell proliferation[1].
Ciprofloxacin (Bay-09867) exhibits potent activity against Y. pestis and B. anthracis with MIC90 of 0.03 μg/mL and 0.12 μg/mL, respectively[2].

ln Vivo

Ciprofloxacin (Bay-09867) (30 mg/kg; i.p.; for 24 hours; BALB/c mice) provides protection against Y. pestis in murine model of pneumonic plague[3].
Ciprofloxacin (Bay-09867) (100 mg/kg; i.e., daily, for 4 weeks; C57BL/6J mice) increases the incidence of aortic dissection and rupture and accelerates the enlargement of the aortic root by decreasing the level of LOX and increasing the activity and levels of MMP in the aortic wall[4].
Ciprofloxacin (Bay-09867) (100 mg/kg; i.e., daily, for 4 weeks; C57BL/6J mice) causes mitochondrial dysfunction, cytosolic DNA sensor signaling activation, and DNA damage and release into the cytosol. Apoptosis and necroptosis in the aortic wall are increased by ciprofloxacin lactate[4].

Cell Assay

Cell Line: Tendon cells
Concentration: 5, 10, 20 and 50 μg/mL
Incubation Time: 24 hours
Result: Decreased the cellularity of tendon cells.

Animal Protocol

30 mg/kg; i.p.

In this assay, 20 g (±4 g) of female BALB/cAnNCrl (BALB/c) mice, 8 to 10 weeks old, are employed. 30 mice are given a single intraperitoneal (i.p.) dose of ciprofloxacin (Bay-09867) at a dose of 30 mg/kg. After receiving Ciprofloxacin for 1 hour, the mice (n = 3/time point/group) are culled at 1, 10, 20, or 30 minutes and at 1, 1.5, 2, 4, 8, or 12 hours later. After receiving DRCFI or CFI for 1 hour, 30 minutes, or 1 hour later, the mice are culled. Ciprofloxacin's short half-life and CFI's longer half-life are taken into consideration when selecting blood sampling locations. After death, blood and the lungs as an entire organ are taken for examination. The concentration of ciprofloxacin in the lung samples at one minute after administration is used to calculate the lung doses after CFI or DRCFI administration.

References

[1]. Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells. Arthritis Rheum. 2008 Jun;58(6):1657-63.

[2]. In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02434-16.

[3]. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91.

[4]. Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice. JAMA Surg. 2018 Sep 1;153(9):e181804.

These protocols are for reference only. InvivoChem does not independently validate these methods.

Physicochemical Properties

Molecular Formula

C17H18FN3O3

Molecular Weight

331.34

Exact Mass

331.13

Elemental Analysis

C, 61.62; H, 5.48; F, 5.73; N, 12.68; O, 14.49

CAS #

85721-33-1

Related CAS #

86393-32-0;93107-08-5;97867-33-9

Appearance

Solid powder

SMILES

C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O

InChi Key

MYSWGUAQZAJSOK-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)

Chemical Name

1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid

Synonyms

Bay-09867; Baflox; Cetraxal; Ciprolin; Bay09867; Fimoflox; Bay 09867;Proflaxin; Spitacin

HS Tariff Code

2934.99.03.00

Storage

Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Solubility Data

Solubility (In Vitro)

DMSO: <1 mg/mL

Water: <1 mg/mL

Ethanol: <1 mg/mL

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

Oral Formulations

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

(Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.0180 mL	15.0902 mL	30.1805 mL
	5 mM	0.6036 mL	3.0180 mL	6.0361 mL
	10 mM	0.3018 mL	1.5090 mL	3.0180 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Mass

Concentration

Volume

Molecular Weight*

Calculate Reset

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

Calculate the Mass of a compound required to prepare a solution of known volume and concentration
Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume

See Example

An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?

Enter 350.26 in the Molecular Weight (MW) box
Enter 10 in the Concentration box and choose the correct unit (mM)
Enter 5 in the Volume box and choose the correct unit (mL)
Click the “Calculate” button
The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Concentration (Start)

Volume (Start)

Concentration (End)

Volume (End)

Calculate Reset

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:

Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
Enter 25 into the Concentration (End) box and select the correct unit (mM)
Enter 25 into the Volume (End) box and choose the correct unit (mL)
Click the “Calculate” button
The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box

Molecular formula

Total molecular weight

g/mol

Calculate Reset

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4 c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Calculate Reset

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
Click the “Calculate” button
The answer appears in the Volume (to add to vial) box

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)

Dosage mg/kg

Average weight of animals g

Dosing volume per animal μL

Number of animals

Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)

% DMSO

% Tween 80

% ddH₂O

Calculate Reset

Calculation results

Working concentration： mg/mL；

Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O，mix and clarify.

Note： (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.

Clinical Trial Information

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03850379	Active Recruiting	Drug: Levofloxacin Drug: Ciprofloxacin	Stem Cell Transplant Complications Prophylaxis	Henry Ford Health System	March 14, 2018	Phase 2
NCT04549311	Active Recruiting	Drug: Antibiotic 1 arm (amoxicillin + clavulanic acid) Drug: Antibiotic 2 arm (ciprofloxacin + metronidazole)	Perianal Abscess Perianal Fistula	Sunnybrook Health Sciences Centre	November 18, 2021	Phase 3
NCT04110340	Recruiting	Drug: Ciprofloxacin Drug: Streptomycin	Plague, Pneumonic Plague, Bubonic	University of Oxford	February 15, 2020	Phase 3
NCT03692715	Recruiting	Drug: Ciprofloxacin Drug: Placebo	Ureteral Stones Ureteral Calculi	Clinical Urology and Epidemiology Working Group	September 27, 2018	Phase 4
NCT05844735	Recruiting	Drug: Ciprofloxacin Drug: Placebo	Rheumatoid Arthritis	Sanofi	May 22, 2023	Phase 1

Biological Data

Postexposure prophylaxis. Shown is the survival of mice infected with Y. pestis following treatment with omadacycline, doxycycline, or ciprofloxacin (all given i.p.). n = 10 for all groups. Antimicrob Agents Chemother . 2017 Apr 24;61(5):e02434-16.

Lung and plasma concentration-time profile of ciprofloxacin administered as intraperitoneal (IP) ciprofloxacin or aerosolized CFI or DRCFI to BALB/c mice. Front Microbiol. 2017 Feb 6;8:91.
Therapeutic efficacy of intraperitoneally delivered ciprofloxacin, aerosolized CFI or DRCFI prophylaxis in a mouse model of inhalational Yersinia pestis infection. Front Microbiol. 2017 Feb 6;8:91.
The effect of ciprofloxacin, CFI or DRCFI prophylaxis on bacterial burden in a mouse model of inhalational Y. pestis infection. Front Microbiol. 2017 Feb 6;8:91.
Increased Susceptibility to Challenge-Induced Aortic Aneurysm and Dissection (AAD) Formation in Mice That Received Ciprofloxacin. JAMA Surg . 2018 Sep 1;153(9):e181804.
Similar Adverse Effects of Ciprofloxacin on Aortic Aneurysm and Dissection (AAD) Development in Male and Female Mice. JAMA Surg . 2018 Sep 1;153(9):e181804.

Decreased Lysyl Oxidase (LOX) Protein Expression and Increased Matrix Metalloproteinase (MMP) Expression and Activity in the Aortic Wall of Challenged Mice That Received Ciprofloxacin. JAMA Surg . 2018 Sep 1;153(9):e181804.